Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU)

J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2487-2490.e1. doi: 10.1016/j.jaip.2019.04.020. Epub 2019 Apr 26.

Authors

Thomas B Casale¹, Thomas R Murphy², Michael Holden³, Yamina Rajput⁴, Bongin Yoo³, Jonathan A Bernstein⁵

Affiliations

¹ University of South Florida, Tampa, Fla.
² Charleston ENT and Allergy, Charleston, SC.
³ Genentech, Inc., South San Francisco, Calif.
⁴ Genentech, Inc., South San Francisco, Calif. Electronic address: rajput.yamina@gene.com.
⁵ Bernstein Clinical Research Center and University of Cincinnati, Cincinnati, Ohio.

PMID: 31034999
DOI: 10.1016/j.jaip.2019.04.020

No abstract available

Publication types

Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anti-Allergic Agents / therapeutic use*
Anxiety
Chronic Urticaria / drug therapy*
Female
Humans
Male
Middle Aged
Omalizumab / therapeutic use*
Patient Reported Outcome Measures
Sleep
Work Performance

Substances

Anti-Allergic Agents
Omalizumab

Associated data

ClinicalTrials.gov/NCT02392624